These inherited differences could partially explain the reason why clinical trials have not shown any effect of PCSK9 inhibitors on increasing the fasting plasma glucose or NOD whereas real-world experience found an association between the use of PCSK9 inhibitors and hyperglycaemia, although primarily related to mild hyperglycaemia rather than diabetes. The gene discussed is PCSK9; the disease is Hyperglycemia.